Clover Health Reports Third Quarter 2026 Financial Results
Clover Health Investments, Corp. announced its financial results for the third quarter of 2026, reporting revenue of $759.3 million.
Stocks · News reference
UBS Adjusts Price Target on Clover Health Investments to $5.50
UBS has raised its price target for Clover Health Investments, Corp. from $5.00 to $5.50 while maintaining a Neutral rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Clover Health Investments Q3 EPS $0.01 Beats $(0.00) Estimate, Sales $759.304M Beat $738.423M Estimate
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
Needham Initiates Coverage of Clover Health Investments with Buy Rating
Needham & Company has initiated research coverage on Clover Health Investments, Corp. with a 'Buy' rating and a price target of $6.00.
Clover Health to Participate in Upcoming UBS Global Healthcare Conference
Clover Health Investments, Corp. announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 UBS Global Healthcare Conference on November 9, 2026.
QUICK SPARK: UnitedHealth Calls 2026 the Bottom for Medicaid Margins
UnitedHealth expects Medicaid margins to bottom in 2026 and improve through 2028, UnitedHealthcare CEO Tim Noel says on earnings call.